Search

Your search keyword '"BOUILLON, R"' showing total 1,526 results
Start Over Author "BOUILLON, R"
1,526 results on '"BOUILLON, R"'

1. Associations of total and free 25OHD and 1,25(OH)2D with serum markers of inflammation in older men

Author

Srikanth, P, Chun, RF, Hewison, M, Adams, JS, Bouillon, R, Vanderschueren, D, Lane, N, Cawthon, PM, Dam, T, Barrett-Connor, E, Daniels, LB, Shikany, JM, Stefanick, ML, Cauley, JA, Orwoll, ES, Nielson, CM, and for the Osteoporotic Fractures in Men (MrOS) Study Research Group

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Inflammatory and immune system, Aged, Aged, 80 and over, Biomarkers, Humans, Inflammation, Interleukin-6, Male, Receptors, Tumor Necrosis Factor, Vitamin D, Elderly, Free 1, 25(OH)(2)D, Free 25OHD, Men, Total 1, 25(OH)(2)D, Total 25OHD, Osteoporotic Fractures in Men (MrOS) Study Research Group, Free 1, 25(OH)2D, Total 1, 25(OH)2D, Biomedical Engineering, Clinical Sciences, Public Health and Health Services, Endocrinology & Metabolism, Clinical sciences, Epidemiology
Abstract

UnlabelledVitamin D is hypothesized to suppress inflammation. We tested total and free vitamin D metabolites and their association with inflammatory markers. Interleukin-6 levels were lower with higher 25-hydroxyvitamin D. 1,25-dihydroxyvitamin D and free 25OHD associations mirrored those of 25OHD. However, associations for the two metabolites diverged for tumor necrosis factor alpha (TNF-α) soluble receptors.IntroductionVitamin D is hypothesized to suppress inflammation, and circulating 25-hydroxyvitamin D (25OHD) and inflammatory markers are inversely correlated. However, total serum 25OHD may not be the best indicator of biologically active vitamin D.MethodsWe tested serum total 25OHD, total 1,25(OH)2D, vitamin D binding protein (DBP), and estimated free 25OHD and free 1,25(OH)2D associations with inflammatory markers serum interleukin-6 (IL-6), TNF-α and their soluble receptors, interleukin-10 (IL-10), and C-reactive protein (CRP) as continuous outcomes and the presence of ≥2 inflammatory markers in the highest quartile as a dichotomous outcome, in a random subcohort of 679 men in the Osteoporotic Fractures in Men (MrOS) study.ResultsIL-6 was lower in men with higher 25OHD (-0.23 μg/mL per standard deviation (SD) increase in 25OHD, 95 % confidence intervals (CI) -0.07 to -0.38 μg/mL) and with higher 1,25(OH)2D (-0.20 μg/mL, 95 % CI -0.0004 to -0.39 μg/mL); free D associations were slightly stronger. 25OHD and DBP, but not 1,25(OH)2D, were independently associated with IL-6. TNF-α soluble receptors were inversely associated with 1,25(OH)2D but positively associated with 25OHD, and each had independent effects. The strongest association with ≥2 inflammatory markers in the highest quartile was for free 1,25(OH)2D (odds ratios (OR) 0.70, 95 % CI 0.54 to 0.89 per SD increase in free 1,25(OH)2D).ConclusionsAssociations of 1,25(OH)2D and free 25OHD with IL-6 mirrored those of 25OHD, suggesting that 1,25(OH)2D and free D do not improve upon 25OHD in population-based IL-6 studies. However, associations for the two metabolites diverged for TNF-α soluble receptor, warranting examination of both metabolites in studies of TNF-α and its antagonists.

Published
2016

6. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus

Author

Khan, A. A., Hanley, D. A., Rizzoli, R., Bollerslev, J., Young, J.E.M, Rejnmark, L., Thakker, R., D’Amour, P., Paul, T., Van Uum, S., Shrayyef, M. Zakaria, Goltzman, D., Kaiser, S., Cusano, N. E., Bouillon, R., Mosekilde, L., Kung, A. W., Rao, S. D., Bhadada, S. K., Clarke, B. L., Liu, J., Duh, Q., Lewiecki, E. Michael, Bandeira, F., Eastell, R., Marcocci, C., Silverberg, S. J., Udelsman, R., Davison, K. Shawn, Potts, Jr, J. T., Brandi, M. L., and Bilezikian, J. P.

Published
2017
Full Text
View/download PDF

18. Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Andalusian patients

Author

Joaquín Dopazo, Bouillon R, Dolores Muñoyerro-Muñiz, Villegas R, Carlos Loucera, Gomez Jmq, Maria Peña-Chilet, Jose Lopez-Miranda, Isaac Túnez, Marina Esteban-Medina, and Jesús Rodríguez-Baño

Subjects
medicine.medical_specialty, business.industry, Mortality rate, Hazard ratio, Retrospective cohort study, chemistry.chemical_compound, chemistry, Internal medicine, Propensity score matching, medicine, Vitamin D and neurology, Calcifediol, business, Cholecalciferol, Survival analysis
Abstract

BackgroundCOVID-19 is a major worldwide health problem because of acute respiratory distress syndrome, and mortality. Several lines of evidence have suggested a relationship between the vitamin D endocrine system and severity of COVID-19.MethodsWe present a retrospective survival study that includes all Andalusian patients hospitalized between January and November 2020 because of COVID-19 infection. Based on a central registry of electronic health records (the Andalusian Population Health Database, BPS), prescription of vitamin D or its metabolites within 15-30 days before hospitalization were recorded. The effect of treatment with vitamin D metabolites for other indication previous to the hospitalization was studied with respect to patient survival by means of Kaplan-Meyer survival curves and Log Hazard Ratios, using a propensity score to compensate the disbalance of compared classes and the confounding factors. The availability of detailed patient data in the BPS allowed to obtain Real-World Evidence (RWE) of the effects of prior use of vitamin D or its metabolites on the mortality due to COVID-19 infection.FindingsA retrospective cohort of 16.401patients was extracted from the BPS, which includes all the patients hospitalized with COVID-19 diagnosis between January and November 2020 in Andalusia, one of the largest regions in Europe with the size of an average median country. A total of 358 patients were found with cholecalciferol, and 193 with calcifediol, prescriptions 15 days before hospitalization. For a period extended to 30 days before hospitalization, the numbers increase to 416 and 210 and, respectively. Kaplan-Meyer survival curves and hazard ratios support an association between consumption of these metabolites and patient survival. Such association was stronger in calcifediol (Log Hazard Ratio, LHR = -1.27±0.32) than in cholecalciferol (LHR= -0.56±0.15), when prescribed 15 days before hospitalization This effect decreases when a larger 30 days period is considered (calcifediol LHR= -1.01±0.27 and cholecalciferol LHR= -0.27±0.12), suggesting that the closer was the treatment to the hospitalization the stronger the association.ConclusionsA significant reduction in mortality in patients hospitalized with COVID-19 is associated with the prescription of vitamin D, especially calcifediol, within 15-30 days prior to hospitalization.

Published
2021
Full Text
View/download PDF

19. Vitamin D: do we get enough?: A discussion between vitamin D experts in order to make a step towards the harmonisation of dietary reference intakes for vitamin D across Europe

Author

Brouwer-Brolsma, E. M., Bischoff-Ferrari, H. A., Bouillon, R., Feskens, E. J. M., Gallagher, C. J., Hypponen, E., Llewellyn, D. J., Stoecklin, E., Dierkes, J., Kies, A. K., Kok, F. J., Lamberg-Allardt, C., Moser, U., Pilz, S., Saris, W. H., van Schoor, N. M., Weber, P., Witkamp, R., Zittermann, A., and de Groot, L. C. P. G. M.

Published
2013
Full Text
View/download PDF

44. Crystallization and preliminary X-ray analysis of the vitamin D-binding protein from human serum

Author

Koszelak, S, McPherson, A, Bouillon, R, and Van Baelen, H

Abstract

The vitamin D-binding protein from human serum has been crystallized from polyethylene glycol as a complex with 25-hydroxyvitamin D3 and examined by X-ray diffraction photography. The space group of the crystals is C2 with a = 203.0 A ̊, b = 75.8 A ̊, c = 90.9 A ̊ and β = 109.5°. There are two molecules of 56,000 dalton in the asymmetric unit. The crystals diffract to about 3.0 Å resolution but the patterns exhibit a substantial level of diffuse scatter. © 1985.

Published
1985

Catalog

Books, media, physical & digital resources
See catalog results